Incentivizing Research for New Uses of Older Approved Drugs (Medicare/Medicaid).
This law creates financial incentives for drug manufacturers to research new uses for medicines that have been approved for at least 10 years. The goal is to speed up the availability of new treatments for diseases where current options are lacking, especially those common among Medicare and Medicaid beneficiaries. This is achieved by adjusting how government rebates are calculated for these specific research drugs.
Key points
Establishes a new category called “Priority Research Drugs” (PRDs) for older medicines being investigated for a new, critical medical need.
Manufacturers researching these PRDs receive relief from mandatory rebates paid to the Medicare and Medicaid programs, encouraging investment in research.
The change encourages the repurposing of existing drugs to treat conditions highly prevalent among federal health program participants.
Introduced
Citizen Poll